OPEN Foundation

Author name: OPEN Foundation

A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment

Abstract

Current treatments for addiction are frequently ineffective. Hallucinogenic therapy has been indicated as helpful for a range of substance use disorders, yet this approach remains understudied and publicly unavailable. It is nonetheless a promising treatment, which has significant, long-term beneficial effects with single doses and a profile characterized by general safety, low toxicity, and non-addictiveness. However, pharmacological interventions, such as hallucinogens, should not be offered if the same effects (e.g. psychological insights/mystical experiences) and outcomes (e.g. decreased drug use) could be achieved absent pharmacological intervention. To date, there have been no clinical comparisons of drug-induced altered states with non-drug-induced states for addiction treatment. We propose and then outline a clinical trial to address this gap in knowledge. The proposed design would evaluate abstinence outcomes in a population of prescription opioid abusers after exposure to one of three conditions: a drug-induced altered state using psilocybin, a non-drug-induced altered state via hyperventilation (Holotropic Breathwork), and an active placebo with niacin. The outcomes of such a study would reveal important differences in therapeutic potential by discriminating hallucinogen-dependent effects from those psychological effects resulting from altered states.

Burdick, B. V., & Adinoff, B. (2013). A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. The American Journal of Drug and Alcohol Abuse, 39(5), 291-297. http://dx.doi.org/10.3109/00952990.2013.811513
Link to full text

A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment Read More »

Psychedelics and Mental Health: A Population Study

Abstract

Background
The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline.

Objective
To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population.

Method
Data drawn from years 2001 to 2004 of the National Survey on Drug Use and Health consisted of 130,152 respondents, randomly selected to be representative of the adult population in the United States. Standardized screening measures for past year mental health included serious psychological distress (K6 scale), mental health treatment (inpatient, outpatient, medication, needed but did not receive), symptoms of eight psychiatric disorders (panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis), and seven specific symptoms of non-affective psychosis. We calculated weighted odds ratios by multivariate logistic regression controlling for a range of sociodemographic variables, use of illicit drugs, risk taking behavior, and exposure to traumatic events.

Results
21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems.

Conclusion
We did not find use of psychedelics to be an independent risk factor for mental health problems.

Krebs, T. S., & Johansen, P. Ø. (2013) Psychedelics and Mental Health: A Population Study. PLoS ONE, 8(8), 1-9. http://dx.doi.org/10.1371/journal.pone.0063972
Link to full text

Psychedelics and Mental Health: A Population Study Read More »

Phylogenetic inference and trait evolution of the psychedelic mushroom genus Psilocybe sensu lato (Agaricales)

Abstract

The genus Psilocybe contains iconic species of fungi renowned for their hallucinogenic properties. Recently, Psilocybe also included non-hallucinogenic species that have since been shifted to the genus Deconica. Here, we reconstruct a multigene phylogeny for Psilocybe, Deconica, and other exemplars of the families Hymenogastraceae and Strophariaceae sensu stricto (s. str.), using three nuclear markers (nLSU-rRNA, 5.8S rRNA, and rpb1). Our results confirm the monophyly of Deconica within Strophariaceae s. str., as well as numerous robust infrageneric relationships. Psilocybe is also recovered as a monophyletic group in the Hymenogastraceae, in which two principal lineages are recognized, including several nested subgroups. Most sections of Psilocybe following classifications based on morphological features are not supported in these analyses. Ancestral character state reconstruction analyses suggest that basidiospore shape in frontal view and spore wall thickness, commonly used to characterize sections in Deconica and Psilocybe, are homoplastic. Chrysocystidia, sterile cells located in the hymenium, evolved on at least two occasions in the Strophariaceae s. str., including in a novel lineage of Deconica.

Ramírez-Cruz, V. Guzmán, G., Villalobos-Arámbula, A. R., Rodríguez, A.,  Matheny, P. B., Sánchez-García, M., & Guzmán-Dávalos, L. (2013). Phylogenetic inference and trait evolution of the psychedelic mushroom genusPsilocybesensu lato (Agaricales). Botany, 91, 573-591. http://dx.doi.org/10.1139/cjb-2013-0070
Link to full text

Phylogenetic inference and trait evolution of the psychedelic mushroom genus Psilocybe sensu lato (Agaricales) Read More »

Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet

Abstract

Methoxetamine (MXE), a ketamine analogue, is one of the new “legal highs” sold on the Internet. The aim of this qualitative study was to provide an initial understanding of what characterizes the experiences induced by MXE. Anonymously written reports (33 persons) on the effects of MXE were collected from public Internet forums and analyzed using the Empirical Phenomenological Psychological Method. The analysis generated 10 themes: (1) preparation, motivation and anticipation; (2) initial effects; (3) malfunction of cognitive processes stabilizing normal state; (4) inner personal processes and learning; (5) emotional processes; (6) altered sensory perception; (7) dissolution and transition; (8) spiritual and transcendental experiences; (9) effects and processes after the experience; (10) re-dosing and addiction.

MXE induced a heavily altered state of consciousness. The effects were similar to those induced by classic hallucinogens (such as LSD, psilocybin) and the dissociative ketamine. MXE seemed to have quite a high abuse potential. Beside the positive effects described, negative effects like fear and anxiety were also reported. Acceptance was considered the best coping strategy. Dissolution of identity and body often culminated in spiritual and transcendental experiences. More research is needed on safety issues, how to minimize harm, and the motivation for using legal highs.

Kjellgren, A., & Jonsson, K. (2013). Methoxetamine (MXE)–a phenomenological study of experiences induced by a “legal high” from the Internet. Journal of psychoactive drugs, 45(3), 276-286. http://dx.doi.org/10.1080/02791072.2013.803647

Link to full text

Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet Read More »

In Memory of Andrew Sewell

The sad news has reached us that Andrew Sewell passed away on Sunday July 21st while he was recovering from surgery. R. Andrew Sewell, MD, was assistant professor of Psychiatry at Yale University where he conducted fascinating research on psyche

delics. We had the pleasure of meeting Andrew at our 2010 Mind Altering Science Conference, where he presented his research as one of our invited speakers.

We will remember Andrew Sewell as a cheerful, optimistic and talented researcher with a gift for inspiring others through his lectures. We feel that his passing away is a great loss for the psychedelic research community. Our deepest sympathies go out to Andrew’s friends and family.

Among other things, Andrew was responsible for writing the well read and sobering manual on how to become a psychedelic researcher, entitled ‘So you want to become a psychedelic researcher?’, a must read for aspiring scientists wanting to study psychedelic substances.

Thank you Andrew, for your contributions to psychedelic research and for your inspiring lectures, filled to the brim with information, delivered at high speed. You’ll be missed.

In Memory of Andrew Sewell Read More »

Confrontation with the Unconscious: Jungian Depth Psychology and Psychedelic Experience

confrontationCarl Gustav Jung pioneered the transformative potential of the deep unconscious. Psychedelic substances provide direct and powerful access to this inner world. How, then, might Jungian psychology help us to better understand the nature of psychedelic experiences? And how might psychedelics assist the movement toward psychological transformation described by Jung?

Jungian depth psychology and psychedelic psychotherapy are both concerned with coming to terms with unconscious drives, complexes, and symbolic images. Unaware of significant evidence for the safe clinical use of psychedelic drugs, Jung himself remained wary of psychedelics and staunchly opposed their therapeutic use. His bias has prevented Jungians from objectively considering the benefits as well as the risks of using psychedelics for psychological healing and growth.

Confrontation with the Unconscious intertwines psychedelic research, personal accounts of psychedelic experiences, and C. G. Jung’s work on trauma, the shadow, psychosis, and psychospiritual transformation — including Jung’s own “confrontation with the unconscious” — to show the relevance of Jung’s penetrating insights to the work of Stanislav Grof, Ann Shulgin, Ronald Sandison, Margot Cutner, among other psychedelic and transpersonal researchers, and to demonstrate the great value of Jung’s penetrating insights for understanding difficult psychedelic experiences and promoting safe and effective psychedelic exploration and psychotherapy.

Scott J. Hill, Ph. D., lives in Sweden, where he conducts scholarly research on the intersection between psychedelic studies and Jungian psychology. He holds degrees in psychology from the University of Minnesota and in philosophy and religion from the California Institute of Integral Studies.

Confrontation with the Unconscious: Jungian Depth Psychology and Psychedelic Experience, by Scott J. Hill, Muswell Hill Press, 252 pages.
Buy this book at bookdepository.com and support the OPEN Foundation.

Confrontation with the Unconscious: Jungian Depth Psychology and Psychedelic Experience Read More »

Confrontation with the Unconscious: Jungian Depth Psychology and Psychedelic Experience

Carl Gustav Jung pioneered the transformative potential of the deep unconscious. Psychedelic substances provide direct and powerful access to this inner world. How, then, might Jungian psychology help us to better understand the nature of psychedelic experiences? And how might psychedelics assist the movement toward psychological transformation described by Jung?

Jungian depth psychology and psychedelic psychotherapy are both concerned with coming to terms with unconscious drives, complexes, and symbolic images. Unaware of significant evidence for the safe clinical use of psychedelic drugs, Jung himself remained wary of psychedelics and staunchly opposed their therapeutic use. His bias has prevented Jungians from objectively considering the benefits as well as the risks of using psychedelics for psychological healing and growth.

Confrontation with the Unconscious intertwines psychedelic research, personal accounts of psychedelic experiences, and C. G. Jung’s work on trauma, the shadow, psychosis, and psychospiritual transformation — including Jung’s own “confrontation with the unconscious” — to show the relevance of Jung’s penetrating insights to the work of Stanislav Grof, Ann Shulgin, Ronald Sandison, Margot Cutner, among other psychedelic and transpersonal researchers, and to demonstrate the great value of Jung’s penetrating insights for understanding difficult psychedelic experiences and promoting safe and effective psychedelic exploration and psychotherapy.

Scott J. Hill, Ph. D., lives in Sweden, where he conducts scholarly research on the intersection between psychedelic studies and Jungian psychology. He holds degrees in psychology from the University of Minnesota and in philosophy and religion from the California Institute of Integral Studies.

Confrontation with the Unconscious: Jungian Depth Psychology and Psychedelic Experience, door Scott J. Hill, Muswell Hill Press, 252 pagina’s.

Koop dit boek via bookdepository.com en steun daarmee Stichting OPEN.

Confrontation with the Unconscious: Jungian Depth Psychology and Psychedelic Experience Read More »

A Different Medicine: Postcolonial Healing in the Native American Church

adifferentmedicineDrawing on two years of ethnographic field research among the Navajos, this book explores a controversial Native American ritual and healthcare practice: ceremonial consumption of the psychedelic Peyote cactus in the context of an indigenous postcolonial healing movement called the Native American Church (NAC), which arose in the 19th century in response to the creation of the reservations system and increasing societal ills, including alcoholism. The movement is the locus of cultural conflict with a long history in North America, and stirs very strong and often opposed emotions and moral interpretations. Joseph Calabrese describes the Peyote Ceremony as it is used in family contexts and federally funded clinical programs for Native American patients. He uses an interdisciplinary methodology that he calls clinical ethnography: an approach to research that involves clinically informed and self-reflective immersion in local worlds of suffering, healing, and normality. Calabrese combined immersive fieldwork among NAC members in their communities with a year of clinical work at a Navajo-run treatment program for adolescents with severe substance abuse and associated mental health problems. There he had the unique opportunity to provide conventional therapeutic intervention alongside Native American therapists who were treating the very problems that the NAC often addresses through ritual. Calabrese argues that if people respond better to clinical interventions that are relevant to their society’s unique cultural adaptations and ideologies (as seems to be the case with the NAC), then preventing ethnic minorities from accessing traditional ritual forms of healing may actually constitute a human rights violation.

A Different Medicine: Postcolonial Healing in the Native American Church, by Joseph D. Calabrese, Oxford Ritual Studies series, Oxford University Press, 256 pages.

Read our review of this book
Buy this book on bookdepository.com and support the OPEN Foundation

A Different Medicine: Postcolonial Healing in the Native American Church Read More »

Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin

Abstract

Emotional face processing is critically modulated by the serotonergic system. For instance, emotional face processing is impaired by acute psilocybin administration, a serotonin (5-HT) 1A and 2A receptor agonist. However, the spatiotemporal brain mechanisms underlying these modulations are poorly understood. Here, we investigated the spatiotemporal brain dynamics underlying psilocybin-induced modulations during emotional face processing. Electrical neuroimaging analyses were applied to visual evoked potentials in response to emotional faces, following psilocybin and placebo administration. Our results indicate a first time period of strength (i.e., Global Field Power) modulation over the 168–189 ms poststimulus interval, induced by psilocybin. A second time period of strength modulation was identified over the 211–242 ms poststimulus interval. Source estimations over these 2 time periods further revealed decreased activity in response to both neutral and fearful faces within limbic areas, including amygdala and parahippocampal gyrus, and the right temporal cortex over the 168–189 ms interval, and reduced activity in response to happy faces within limbic and right temporo-occipital brain areas over the 211–242 ms interval. Our results indicate a selective and temporally dissociable effect of psilocybin on the neuronal correlates of emotional face processing, consistent with a modulation of the top-down control.

Bernasconi, F., Schmidt, A., Pokorny, T., Kometer, M., Seifritz, E., & Vollenweider, F. X. (2013). Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral Cortex, bht178. 10.1093/cercor/bht178
Link to full text

Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin Read More »

Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression

Abstract

OBJECTIVES:
Ketamine and other NMDA (N-methyl-D-aspartate) antagonists produce fast-acting antidepressant-like effects, although the underlying mechanism is unclear. Furthermore, high affinity NMDA antagonists such as ketamine are associated with psychotomimetic effects. To date the link between the antidepressant and psychotomimetic effects of ketamine has not been explored. We examined the relationship between the antidepressant and psychotomimetic effects of a single ketamine infusion in subjects diagnosed with major depressive disorder.
METHODS:
In a double-blind, cross-over, placebo-controlled, two weeks clinical trial we studied the effects of ketamine (0.54 mg/kg within 30 min) in a group of 27 hospitalized depressive patients.
RESULTS:
Higher intensity of psychotomimetic symptoms, measured using BPRS, during ketamine administration correlated with alleviation in mood ratings during the following week with maximum on day seven. Ketamine was superior to placebo in all visits (day 1, 4, and 7) assessed by MADRS with effect size (Cohen´s d) of 0.62, 0.57, and 0.44 respectively. There was no significant correlation between ketamine and nor-ketamine plasma levels and MADRS score change at any study time point.
CONCLUSION:
The substantial relationship between ketamine’s antidepressant and psychotomimetic effects was found. This relationship could be mediated by the initial steps of ketamine’s action, trough NMDA receptors, shared by both ketamine’s clinical effects.
Sos, P., Klirova, M., Novak, T., Kohutova, B., Horacek, J., & Palenicek, T. (2013). Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinology Letters34(4), 287-293.
Link to full text

Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression Read More »

Women and Psychedelics: Cycles, Care, and Conditions - October 23rd